Capital Fund Management S.A. Takes $594,000 Position in Takeda Pharmaceutical Co. $TAK

Key Points

• Capital Fund Management S.A. acquired a new stake in Takeda Pharmaceutical Co., purchasing 39,946 shares valued at approximately $594,000.
• Institutional investors collectively own 9.17% of Takeda's stock, with several hedge funds increasing their positions during the first quarter.
• Takeda's latest earnings report showed earnings of $0.52 per share, surpassing estimates, although revenue fell short of expectations at $7.45 billion.

Capital Fund Management S.A. purchased a new stake in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 39,946 shares of the company's stock, valued at approximately $594,000.

Other hedge funds have also modified their holdings of the company. Brooklyn Investment Group lifted its stake in Takeda Pharmaceutical by 890.7% in the 1st quarter. Brooklyn Investment Group now owns 12,176 shares of the company's stock valued at $181,000 after buying an additional 10,947 shares in the last quarter. Corient IA LLC purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $595,000. American Century Companies Inc. lifted its position in shares of Takeda Pharmaceutical by 5.0% in the first quarter. American Century Companies Inc. now owns 316,208 shares of the company's stock valued at $4,702,000 after acquiring an additional 15,121 shares in the last quarter. Boston Partners boosted its stake in shares of Takeda Pharmaceutical by 91.2% during the first quarter. Boston Partners now owns 132,107 shares of the company's stock valued at $1,964,000 after acquiring an additional 63,024 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Takeda Pharmaceutical during the 1st quarter worth about $125,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Takeda Pharmaceutical from a "hold" rating to a "strong sell" rating in a report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold".

Takeda Pharmaceutical Trading Up 0.1%

Shares of TAK stock traded up $0.02 during mid-day trading on Friday, hitting $14.99. 1,746,970 shares of the company's stock were exchanged, compared to its average volume of 3,637,950. The stock has a market cap of $47.68 billion, a price-to-earnings ratio of 49.95 and a beta of 0.22. The company has a quick ratio of 0.59, a current ratio of 1.16 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.56. The stock has a 50-day simple moving average of $14.80 and a two-hundred day simple moving average of $14.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.